AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Three new antilipid drugs. (Cardiology).

OB GYN News

| April 01, 2002 | Kubetin, Sally Koch | COPYRIGHT 2002 International Medical News Group. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

Nicostatin, rosuvastatin, and ezetimibe are three new lipid-lowering drugs that are likely to be approved this year, Dr. Donald B. Hunninghake predicted at a conference sponsored by the American College of Cardiology.

Nicostatin (Advicor) received Food and Drug Administration approval in December. Rosuvastatin and ezetimibe are expected to win FDA approval without difficulty later this year, said Dr. Hunninghake of the University of Minnesota, Minneapolis.

All three drugs have excellent safety profiles. Each offers notable advantages over existing therapies in terms of efficacy and/or convenience, he said.

Nicostatin combines extended-release niacin with lovastatin. The combined effects of the two drugs on LDL, HDL, and triglycerides are greater ...

Related articles from newspapers, magazines, journals, and more
WelChol and Ezetimibe Combination Therapy Provides Significant LDL-C Reductions.
Press release article from: PR Newswire November 13, 2006 700+ words
...the lipoprotein ratios LDL-C/HDL-C, TC/HDL...percentage of patients achieving LDL-C targets of < 100...WelChol is indicated for LDL-C lowering and was approved by the U.S. Food and Drug Administration (FDA) for marketing in...
First Study to Evaluate WelChol/Ezetimibe and Simvastatin Effect on LDL-C Finds...
Press release article from: PR Newswire November 13, 2006 700+ words
...mean absolute changes in LDL-C/HDL-C, TC/HDL...percentage of patients achieving LDL-C target of < 70...WelChol is indicated for LDL-C lowering and was approved by the U.S. Food and Drug Administration (FDA) for marketing in...
FDA Approves VYTORIN -TM- -ezetimibe/simvastatin-, the First and Only Product...
Press release article from: Business Wire July 23, 2004 700+ words
...Pharmaceuticals VYTORIN(TM) lowered LDL cholesterol by 52 percent at...today that the U.S. Food and Drug Administration has approved VYTORIN(TM...simvastatin) for the treatment of high LDL cholesterol (LDL-C) in patients with primary...
Indianapolis-Based PTS to Market World's First In-Office Direct LDL Cholesterol...
Press release article from: PR Newswire June 12, 2006 700+ words
...Physicians use the direct LDL Test Strip with the portable...handheld analyzer. The direct LDL color-coded MEMo chip(TM...clearance from the Food and Drug Administration for a new HDL cholesterol test...Total Cholesterol, direct LDL Cholesterol, HDL Cholesterol...
This Release Was Previously Issued: FDA Approves VYTORIN -TM-...
Press release article from: Business Wire July 26, 2004 700+ words
...Pharmaceuticals VYTORIN(TM) lowered LDL cholesterol by 52 percent at...today that the U.S. Food and Drug Administration has approved VYTORIN(TM...simvastatin) for the treatment of high LDL cholesterol (LDL-C) in patients with primary...
Welchol(R) (colesevelam HCl) Receives FDA Approval to Lower LDL Cholesterol in...
Press release article from: PR Newswire October 7, 2009 700+ words
...today that the U.S. Food and Drug Administration (FDA) has approved the supplemental...density lipoprotein cholesterol (LDL-C) in boys and postmenarchal...Originally approved in 2000 for LDL-C lowering and in 2008 for...exercise to reduce elevated LDL-C in adults with primary...
Study Results Found Low-Dose Orlistat (60 mg) Demonstrates Significant...
Press release article from: PR Newswire October 22, 2006 700+ words
...effect low-dose orlistat had. LDL cholesterol levels returned...mg of orlistat with elevated LDL levels at baseline and there was a persistent reduction in LDL cholesterol levels, even after...review by the U.S. Food and Drug Administration (FDA), orlistat 60 mg...
AstraZeneca's CRESTOR(R) (rosuvastatin calcium) Receives FDA Approval; CRESTOR...
Press release article from: PR Newswire August 12, 2003 700+ words
...approval from the U.S. Food and Drug Administration (FDA) as an adjunct to diet...40 mg dose, CRESTOR lowered LDL- cholesterol by 45 to 63 percent...CRESTOR 10 mg to 40 mg reduced LDL-cholesterol by 46 percent...atorvastatin 10 mg to 80 mg reduced LDL-cholesterol by 37 percent...
For more facts and information, see all results
©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA